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Molecul ar Method
The use of SNaPshot (Applied Biosystems, Foster City, CA) for 
predicting blood group antigens has emerged as an alternative to 
hemagglutination testing and also to the current low- and high-
throughput blood group genotyping methods. Several groups have 
developed multiplex–polymerase chain reaction SNaPshot assays 
to determine single nucleotide polymorphisms (SNPs) in blood 
group genes with the purpose of identifying clinically relevant 
antigens and rare alleles. The selection of SNPs is based on the 
population or laboratory reality and the purpose of the geno-
typing. Unlike high-throughput genotyping strategies that are 
provided as commercial platforms, the SNPs can be chosen to best 
meet the needs of the user, and the interpretation of the results 
do not depend on the manufacturer. Immunohematology 
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SnaPshot (Applied Biosystems, Foster City, CA) is a 
minisequencing assay based on a single nucleotide 
primer extension capable of detecting single nucleotide 
polymorphisms (SNPs).1 Minisequencing was first described 
in the 1990s2–7 and was used to detect SNPs in apolipoprotein 
E genotyping4 and in cystic fibrosis genotyping.2,7 Although 
the minisequencing reaction differs from SNaPshot, the basic 
principle of the method remains the same. The first reports 
used assays based on an internal reaction performed with 
an internal primer that ends exactly at 5´ of each SNP/point 
mutation site and radioisotope-labeled nucleotides for a specific 
allele. The assays varied in format, method of detection, ability 
to multiplex, and complexity.1
Using fluorescent-labeled nucleotides and an automated 
sequencer, the SNaPshot method follows the same principle 
as minisequencing.8–10 The steps involved in SNaPshot are 
illustrated in Figure 1. The approach consists of a multiplex 
polymerase chain reaction (PCR) containing amplicons 
flanking selected SNPs. In the example, four hypothetic 
genes are amplified with forward and reverse primers 
comprising all SNPs of interest. While designing multiplex 
PCR primers, two SNPs can be included in the same 
amplicon when fragment size allows, as demonstrated in 
Gene 2 (Fig. 1A). Following multiplex PCR, electrophoresis 
in agarose gel could be performed to verify amplification of 
all fragments. The multiplex PCR product is purified with 
exonuclease and alkaline phosphatase. After purification, 
an internal reaction is carried out with an internal primer 
for each SNP, dideoxynucleotides (ddNTPs) labeled with 
different fluorescent dyes, and a polymerase enzyme. Internal 
primers can be designed to anneal with both directions of 
DNA, but they purposely end exactly one nucleotide before 
the polymorphism and present repetitive nucleotide tails 
to ensure that they differ in size (Fig. 1B). At the end of the 
internal reaction, primers with different-sized tails presenting 
ddNTPs with different colors attached represent the alleles. In 
the case of a heterozygous allele, both possibilities of ddNTP 
incorporation appear (Fig. 1C). The reaction is denatured, size 
Fig. 1. Schematic representation of SNaPshot. (A) Multiplex poly-
merase chain reaction (PCR). (B) Internal primers. (C) Fragments 
after internal primer reaction. (D) Sample genotype using a specific 
software: Gene1*A/Gene1*B, Gene2*A/Gene2*A, Gene2*Y/Gene2*Y, 
Gene3*A/Gene3*A, Gene4*B/Gene4*B.
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standard is added, and the fragment analysis is performed 
in a capillary-based sequencer. Amplicons are separated 
according to size, and the fluorescent dye is detected. These 
combinations represent all possible alleles. Fragment analysis 
is evaluated using specific software (Fig. 1D).
Internal or probe primers are the key point of the SNaPshot 
reaction, as they are responsible for the SNP identification 
and allele discrimination. SNPs are identified by the internal 
primers, as they are designed to show different sizes recognized 
during migration in the sequencing analyzer. These sizes 
are determined by a tail added to the 5´ end of each internal 
primer, which could be a poly(A), (C), (C), or (G), or a missense 
repeated sequence. While designing internal primers, their 
migration through capillary electrophoresis in the sequencer 
should be considered, as the distance among the peaks must 
be clear and each fluorescent dye has an individual weight that 
also interferes on migration. Moreover, because each internal 
primer ends exactly one nucleotide before the SNP, the allele 
will be determined when the ddNTP is incorporated. For these 
two reasons, internal primers are crucial in this approach.1,11
Another fundamental feature of SNaPshot is the use of 
ddNTPs instead of deoxynucleotides (dNTPs) in internal 
reactions because the ddNTPs lack the hydroxyl-radical. 
Because of this lack, when the internal primer is hybridized in 
the target sequence, a ddNTP is incorporated in the internal 
primer 3´ end where the SNP is located and the reaction stops. 
As each allele is characterized by a different nucleotide, the 
fluorescent dye present in ddNTP will identify the genotype.1,11
Therefore, at the end of the reaction, we obtain several 
amplicons with singular lengths and with different fluorescent 
dyes that correspond to a particular combination between 
migration and color. This precise combination is analyzed 
using specific software capable of predicting the allele. 
In general, this software is provided with the automated 
sequencer, and compares the obtained migration pattern of 
the sample with a prior defined panel. The better way to build 
this panel would be to perform the reactions with previously 
genotyped samples, including those heterozygous for every 
allele. Software interpretation will provide the genotype, and 
phenotype can be easily predicted.
SNaPshot and Blood Group Genotyping
Although serology is the gold standard method used 
in immunohematology, it has certain limitations. These 
limitations include labor-intensive hemagglutination testing 
and data entry, the lack and high cost of commercial reagents, 
and a paucity of potent antisera.12,13 Because the molecular 
basis of the majority of blood group antigens is known, this 
knowledge, together with the availability of DNA test methods, 
are being used to determine the genotype and to predict the 
phenotype of an individual.14,15 Considering this scenario, 
several methods of blood group genotyping were incorporated 
in the clinical laboratory and SNaPshot was evaluated as a 
medium-throughput option.12
Several groups have already reported the use of the 
SNaPshot method to detect blood group SNPs.11,16–24 Table 1 
summarizes their findings, including alleles identified, the 
purpose of the studies, number of SNPs detected, number of 
reactions, number of tested samples, and validation features. 
Reviewing these, we can conclude that the choice of the 
approach was supported based on the limitations of serologic 
methods, on throughput, and on good feasibility regardless of 
DNA quality.
In summary, the approaches presented in Table 1 were 
developed with the focus on forensic identification and on 
genotyping of a group of alleles with specific goals, which 
included predicting clinically relevant Rh and low-incidence 
antigens. The number of investigated SNPs varied from 5 
to 39 depending on the purpose and standardization of the 
protocols.
An additional important feature addressed in Table 1 
is validation, where primer concentration and migration 
pattern in fragment analysis are evaluated. For that reason, 
testing previously genotyped samples or performing parallel 
genotyping with known methodologies is required.11,16,17,21–23 
Additionally, samples comprising all known alleles are 
necessary to inform the software where the peaks should be 
to build the panel of analyses. Hence, the inclusion of hetero-
zygous samples certainly helps the validation process.11 Blood 
group genotyping results obtained with SNaPshot were mainly 
validated by comparing them with those from previously 
genotyped11,22,23 or phenotyped samples when commercial 
reagents were available.16,17,21 Interestingly, sequencing results 
were concordant with the SnaPshot results, even when the 
results were discordant with those obtained with allele-specific 
PCR16 or restriction fragment length polymorphism analysis of 
PCR-amplified fragments (PCR–restriction fragment-length 
polymorphism [RFLP]).11
Strengths and Limitations
SNaPshot emerged as a technology capable of genotyping 
several polymorphisms in a single reaction. As a medium 
to the high-throughput method, it meets quite a few service 
realities. This robust approach improves the throughput of 
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methodologies such as PCR-RFLP and allele-specific PCR, 
while maintaining the flexibility for customization, making it, 
like an “in-house” protocol, easily adaptable to the user’s needs. 
Conversely to high-throughput genotyping strategies such as 
commercial microarrays, SNPs can be chosen to best meet the 
needs of patients and donors, SNPs for uncommon antigens 
can be included, and the interpretation of the results does not 
depend on the manufacturer.11,15,25
If indicated, the protocol can be adapted to allow for 
the addition of SNPS following validation. As an example, 
our laboratory decided to include genotyping of SMIM1 
to predict the Vel antigen in our SNaPshot standardized 
for identification of rare alleles, after the publication of its 
molecular background.26–28 Although the event was not an 
SNP, but a 17-bp deletion, inclusion was possible because the 
internal primer was designed upstream from the deletion and 
the subsequent nucleotide differs if deletion is present. Figure 
2A shows the internal primer location and ddNTP related to 
each allele. To allow fragment analysis (Fig. 2B), the internal 
primer was designed with a longer polyA tail. To validate the 
assay, we used samples previously genotyped by the described 
PCR-RFLP protocol.26
Moreover, the upgrade performed in our developed 
SNaPshot protocol for rare blood group alleles showed that 
this method is not exclusive for SNP analysis, which is another 
advantage of the method. Knowledge of the SNaPshot principle 
and the molecular bases of blood group polymorphisms allows 
for different applications of the approach.
Another important benefit of SNaPshot is the sensitivity 
of the method. Previous reports tested samples with geno-
mic DNA concentration ranging from 4.3 to 529.0 ng/μL11 
and 0.1 ng template genomic DNA17 with positive results. 
Corroborating, SNaPshot has been used in forensic genetics, 
showing achievement of good results with poor-quality 
Table 1. Outline of reports on SNaPshot to determine blood group antigens
Blood group alleles Aim
Number of tested SNPs/ 
Number of multiplex 




samples Validation method Reference
KEL*3/KEL*4, KEL*6/KEL*7, DI*1/DI*2, 
DI*3/DI*4, YT*1/YT*2, CO*1/CO*2, 





Latini et al. (2014, 
Brazil)11






for clinically relevant 
phenotypes
11/1/1 227 Allele-specific PCR, 
sequencing, and 
serology 
Di Cristofaro et al. (2010, 
France)16
ABO alleles Forensic 
identification
6/1/1 127 PCR-RFLP and 
serology 
Doi et al. (2004, Japan)17
ABO alleles Forensic 
identification
5/1/1 70 — Ferri et al. (2004 and 
2009, Italy)18,19




39/1/5 152 Analysis of 16 paternity 
test cases and 1 
personal identification
Inagaki et al. (2004, 
Japan)20
FYAB, GATA, FYX, DOA/B1, DOA/
B2, DOA/B3, DOJOA, DOHY, LWA/B, 





17/3/3 29 Previously genotyped 
and/or phenotyped 
samples
Palacajornsuk et al. 
(2009, United States)21
6 variant RHCE*ce, KEL*6/KEL*7 Knowledge of 
RHCE and KEL 
allele frequencies to 
reduce alloantibody 
formation
6/1/1 1205 Previously genotyped 
samples
Silvy et al. (2011, 
France)22
13 variants of weak D and DEL Simultaneous 
detection of 14 RHD 
SNPs
14/1/1 152 Exon-specific PCR 
and sequencing
Silvy et al. (2011, 
France)23
17 alleles in MNS, Kell, Duffy, Kidd, 
Cartwright, Dombrock, Indian, Colton, 
Diego, and Landsteiner–Wiener 
systems
Description of 
antigen prevalence  
to improve 
transfusion practice
21/2/2 599 Genotyping of the 





Mazières et al. (2013, 
France)24
SNP = single nucleotide polymorphism; PCR = polymerase chain reaction; RFLP = restriction fragment-length polymorphism.
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samples, including formalin-fixed paraffin-embedded 
tissues,29 heat-degraded samples,17 and DNA extracted from 
bones, teeth, muscles, organs, nails, semen-contaminated 
vaginal fluid, and aged dried blood on blood type test paper.17,20
When SNaPshot costs are analyzed and compared 
with other methods, we conclude that it can be an excellent 
option. Depending on the reality, commercial platforms may 
be very expensive and in-house strategies become an option 
to perform genotyping.14,25 Depending on the study, reagent 
cost may vary from $0.96 to $2.00 per detected SNP.11,21 In 
our experience, after standardization, costs were successfully 
decreased because reagent volume could be reduced while 
maintaining quality.11 When compared with low-throughput 
methods such as PCR-RFLP, for which costs were estimated 
to be $1.08 per SNP, required time until final results could be 
14-fold reduced in SNaPshot (even though the resource costs 
are similar).11 Evaluating another study that analyzed 35 red 
blood cell antigens, estimated cost per antigen was $0.48 
using multiplex PCR and $1.97 to $2.14 using conventional 
serology.30 These approaches suggest that noncommercial 
assays present similar costs per SNP, although they differ on 
throughput and turnaround time.11,21,30 On the other hand, 
platforms such as microarrays may differ in cost depending on 
the country, but are an excellent option when considering time 
and throughput.12
Moreover, as with other genotyping strategies, automation 
is possible and several samples can be simultaneously 
analyzed. A sequencer is the required equipment for SNaPshot, 
in particular a capillary electrophoresis–based sequencer, and 
therefore the throughput depends on the equipment used. 
Speed is related to the number of capillaries in the sequencer 
and pipetting, which can range from manual (single or 
multichannel) and repetition to adjustable platforms.
SNaPshot is a method from Applied Biosystems, and 
therefore the reagents, equipment, and software are acquired 
from this company.
The main challenges of implementation of this approach 
are primer design and validation. Primer design comprises 
PCR multiplex and internal reaction steps. Bioinformatics tools 
may help avoid undesirable matches, although meticulous 
testing is required. Structures like hairpin, self-dimer, and 
heterodimers must be avoided. Concentration of pairs of 
primers for multiplex PCR and internal primers for internal 
reaction must be adjusted. Amplification of all fragments in 
multiplex PCR is monitored by agarose gel electrophoresis, 
and internal primer performance is verified by fragment 
analysis.
Furthermore, validation with heterozygous samples 
for every SNP previously genotyped by other methods is 
mandatory,11 because building of the software panel for the 
result’s analysis must include all possible alleles. This step 
can be problematic, as heterozygous samples could be rare 
if low-incidence antigens are being analyzed. The number of 
samples for validation depends on the protocol and laboratory 
requirements, but at least one heterozygous sample per SNP 
is mandatory. Discrepancies with other genotyping methods 
and phenotyping results are common during validation. When 
genotyping results differ, sequencing agrees with SNaPshot.11,16 
Divergence with phenotyping is more frequent, as secondary 
genetic alterations are described to affect protein expression, 
such as the GATA change that influences Duffy expression. 
Fig. 2. Inclusion of genotyping to predict Vel antigen in our multiplex 
SNaPshot reaction for detection of 16 blood group alleles. (A) The 
17-bp deletion in exon 3 of SMIM1 associated with Vel– phenotype 
is highlighted in gray and the internal primer used is underlined. Red 
arrows indicate ddNTPs incorporated depending on the genotype. 
For Vel+ phenotype, an adenine (ddNTP) is incorporated after the 
internal primer, whereas for Vel– phenotype, a cytosine (ddNTP) 
is incorporated. Heterozygous samples present both adenine 
and cytosine. (B) Analysis (Gene Mapper, Applied Biosystems) 
of representative samples emphasizing genotyping to predict Vel 
antigen. First picture is a heterozygous sample with the presence of 
both alleles; in the second picture, the 17-bp deletion is present in 
both alleles, and therefore only cytosine (ddNTP) is detected; and in 
the last picture, both alleles have adenine. 
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The success of the final protocol can be exhaustive until 
reaching ideal primer design/concentration and validation.
Final Consideration
After overcoming the barriers of protocol standardization, 
SNaPshot can be a cost-effective, practical, and robust 
molecular strategy for medium- to high-throughput geno-
typing. Depending on the user’s needs, SNaPshot allows 
grouping SNPs of interest, which is an excellent alternative 
when there is a specific purpose.  In our experience, including 
polymorphisms related to rare blood group alleles in a single 
reaction was the best way to screen rare donors and supply our 
rare donor program.11
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